A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients

• Main Authors: Elena Campione (Author), Sara Lambiase (Author), Ruslana Gaeta Shumak (Author), Marco Galluzzo (Author), Caterina Lanna (Author), Gaetana Costanza (Author), Cristiana Borselli (Author), Fabio Artosi (Author), Terenzio Cosio (Author), Lorenzo Tofani (Author), Annunziata Dattola (Author), Francesca Di Daniele (Author), Luca Bianchi (Author)
• Format: Book
• Published: MDPI AG, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaqu...